Sarepta Therapeutics (SRPT) Tops Q2 EPS by 42c, Beats on Revenue
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $0.64, $0.42 better than the analyst estimate of $0.22. Revenue for the quarter came in at $401.3 million versus the consensus estimate of $383 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent posts a blowout Q4 and aggressive guidance, yet shares take a 5% haircut
- Perma-Fix (PESI) Misses Q2 EPS by 15c
- Talphera (TLPH) Reports In-Line Q2 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
